Prospective randomized trial of everolimus- and zotarolimus-eluting stents for treatment of unprotected left main coronary artery disease: ISAR-LEFT-MAIN-2.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Everolimus (Primary) ; Zotarolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms ISAR-LEFT-MAIN-2; LEFT-MAIN-2

08 Aug 2013 Primary endpoint 'Major-adverse-cardiac-event-rate' has not been met according to results published in the Journal of the American College of Cardiology.
08 Aug 2013 Results published in the Journal of the American College of Cardiology.
04 Jan 2012 Additional lead trial investigator identified and actual patient number is 650 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com